235 related articles for article (PubMed ID: 30827867)
1. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
Sharma K; Tanwar O; Deora GS; Ali S; Alam MM; Zaman MS; Krishna VS; Sriram D; Akhter M
Bioorg Med Chem; 2019 Apr; 27(7):1421-1429. PubMed ID: 30827867
[TBL] [Abstract][Full Text] [Related]
2. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
[TBL] [Abstract][Full Text] [Related]
4. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
5. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
Desai NC; Trivedi AR; Khedkar VM
Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD
Wang X; Ahn YM; Lentscher AG; Lister JS; Brothers RC; Kneen MM; Gerratana B; Boshoff HI; Dowd CS
Bioorg Med Chem Lett; 2017 Sep; 27(18):4426-4430. PubMed ID: 28827112
[TBL] [Abstract][Full Text] [Related]
7. Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis.
Ramesh D; Joji A; Vijayakumar BG; Sethumadhavan A; Mani M; Kannan T
Eur J Med Chem; 2020 Jul; 198():112358. PubMed ID: 32361610
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
9. Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors.
Naidu KM; Nagesh HN; Singh M; Sriram D; Yogeeswari P; Gowri Chandra Sekhar KV
Eur J Med Chem; 2015 Mar; 92():415-26. PubMed ID: 25590862
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 6-[4-(4-Propoxyphenyl)piperazin-1-yl]-9H-purine Derivatives as Antimycobacterial and Antifungal Agents: In Vitro Evaluation and In Silico Study.
Nadaf AQA; Najare MS; Garbhagudi M; Mantur S; Sunagar MG; Gaonkar S; Joshi S; Khazi IAM
Chem Biodivers; 2020 May; 17(5):e2000053. PubMed ID: 32170847
[TBL] [Abstract][Full Text] [Related]
11. Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors.
Krishna VS; Zheng S; Rekha EM; Nallangi R; Sai Prasad DV; George SE; Guddat LW; Sriram D
Eur J Med Chem; 2020 May; 193():112178. PubMed ID: 32171154
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Antimicrobial Evaluation and Molecular Docking of Some Potential 2,6-disubstituted 1H-Benzimidazoles; Non-Classical Antifolates.
Harer S; Bhatia M; Kawade V
Med Chem; 2019; 15(7):813-832. PubMed ID: 30727904
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.
Desai NC; Somani H; Trivedi A; Bhatt K; Nawale L; Khedkar VM; Jha PC; Sarkar D
Bioorg Med Chem Lett; 2016 Apr; 26(7):1776-83. PubMed ID: 26920799
[TBL] [Abstract][Full Text] [Related]
14. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
15. Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Samala G; Nallangi R; Devi PB; Saxena S; Yadav R; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Aug; 22(15):4223-32. PubMed ID: 24953948
[TBL] [Abstract][Full Text] [Related]
16. Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitors.
Sahu NU; Singh V; Ferraris DM; Rizzi M; Kharkar PS
Bioorg Med Chem Lett; 2018 Jun; 28(10):1714-1718. PubMed ID: 29699922
[TBL] [Abstract][Full Text] [Related]
17. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
Sriram D; Aubry A; Yogeeswari P; Fisher LM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis.
Nandikolla A; Srinivasarao S; Khetmalis YM; Kumar BK; Murugesan S; Shetye G; Ma R; Franzblau SG; Sekhar KVGC
Toxicol In Vitro; 2021 Aug; 74():105137. PubMed ID: 33684466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
